

SNJ Pharma Inc

SNJ101: Safer than tPA

Hyeon J Kim, Ph.D.
President
hjkim@snjpharma.com




THROMBOSIS & THROMBOLYTICS

250 M

1 Drug

10X Bleeding


Exclusion Criteria




Inclusion Criteria



UNMET NEEDS




SNJ101 (recombinant HtrA1): Safer than tPA




SNJ101: Normal wound healing without bleeding


(1) No bleeding from the excised wounds



(2) No lysis of fibrin in wound clots




(3) No excessive bleeding from wounds in a mouse tail bleeding assay




SNJ101: Superior efficacy compared to tPA


Thrombosis





















Pulmonary Embolism



Large Vessel Occlusion




COMPETITIVE LANDSCAPE

Intervention	Drug/Procedure	Thrombi Removal	No Plasmin	Normal Clotting	Normal Bleeding	No Windows	Disadvantages or Advantages
Plasminogen Activator	tPA (Alteplase, Tenecteplase)						Bleeding risks
Anti-coagulant	Warfarin, Heparin, Eliquis		n.a.			n.a.	Indirect prevention Bleeding risks
Anti-platelet	Aspirin, Clopidogrel		n.a.			n.a.	Indirect prevention Bleeding risks
Mechanical Device	Endovascular Thrombectomy		n.a.	n.a.	n.a.		Limited to LVO Limited access
Thrombase	rHtrA1 (SNJ101)						No plasmin No hemorrhage Normal wound healing

n.a.: not applicable

THE MARKET OPPORTUNITY




- ❑ **Total Addressable Market**
= (10% of patients X \$10K) = \$250B
- ❑ **Serviceable Available Market**
= (33% of TAM) = \$83B
- ❑ **Serviceable Obtainable Market**
= (30% of SAM) = \$25B

INTELLECTUAL PROPERTY

- 
- A light blue world map is centered in the background of the slide, showing the continents in white against a blue ocean.
- ✓ Thrombolytic agents for Intravascular clots
 - ✓ 2 Granted patents
 - ✓ 1 PCT & 9 Pending patents (US, CA, EU, JP, etc.)

PROJECT PLAN TO EXIT



HEALTH ECONOMICS & REIMBURSEMENT



- 
- ✓ Thrombase safer than tPA
 - ✓ Strong support data and strong IP
 - ✓ Asking for strategic partners and investors

SNJ Pharma Inc, Hyeon J Kim, hjkim@snjpharma.com